Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Case Reports
Share your love
Understanding Tear Composition and Function in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Identification and Diagnosis of Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
SparingVision doses first patient in NYRVANA clinical trial of SPVN20 for retinitis pigmentosa | Ophthalmology Times
(Image Credit: AdobeStock/Davizro Photography) SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis pigmentosa (RP). NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability,…
The future of glaucoma care: Where innovation meets everyday practice | Ophthalmology Times
Specialists in glaucoma care share insights on evolving strategies, technologies, and treatments shaping the future of patient management. (Image credit: AdobeStock) As glaucoma care continues to advance, ophthalmologists are embracing innovative technologies and new approaches that are reshaping diagnosis and…
New data from Sweden highlight lesion features that accelerate GA growth | Ophthalmology Times
(Image Credit: AdobeStock/Alexey Novikov) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science…
Research supports that iron dysregulation may drive AMD | Ophthalmology Times
Image credit: AdobeStock/Gorodenkoff A new study supports the hypothesis that iron dysregulation may be a driver of dry age-related macular degeneration (AMD). This could be especially true in the early stage of geographic atrophy (GA). According to the research, the…
Q&A: William F. Wiley, MD, on what BVI’s trifocal IOL approval means for US premium vision options | Ophthalmology Times
The FDA’s approval of the FineVision HP trifocal lens expands the range of premium lens option to US ophthalmologists and their patients. (Image credit: AdobeStock/Margarita Ratatosk) As the landscape of ophthalmic innovation continues to evolve, new technologies are reshaping how…
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment | Ophthalmology Times
The FDA has requested additional evidence for Sydnexis’ SYD-101, a 0.01% atropine eye drop aimed at slowing myopia progression in children, despite positive outcomes from the STAR clinical trial. (Image credit: Ophthalmology Times) The FDA has sent a complete response…
The mechanics of presbyopia: From muscle movement to functional vision | Ophthalmology Times
(Image Credit: AdobeStock) Presbyopia-correcting eye drops share a common mechanism: They are miotic agents designed to create a smaller pupil. The power of the pupil to extend depth of focus is impressive, as observed in patients with smaller pupils who…
Rethinking punctal occlusion as an option for allergic conjunctivitis | Ophthalmology Times
(Image Credit: AdobeStock) The intracanalicular dexamethasone ophthalmic insert (Dextenza; Ocular Therapeutix) incorporates 0.4 mg of dexamethasone into the hydrogel matrix to treat postoperative inflammation and pain following ocular surgery. It is also approved for the treatment of ocular itching associated…